Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina

• Published in: Mycoses 2016-06, Vol.59 (6), p.351-356
• Main Authors: Córdoba, Susana, Isla, Maria G., Szusz, Wanda, Vivot, Walter, Altamirano, Rodrigo, Davel, Graciela
• Format: Article
• Language: English
• Subjects: AIDS-Related Opportunistic Infections - microbiology; AIDS-Related Opportunistic Infections - mortality; Amphotericin B - pharmacology; Antifungal Agents - pharmacology; antifungal drugs; Argentina; Argentina - epidemiology; Cryptococcosis - epidemiology; Cryptococcosis - microbiology; Cryptococcus neoformans; Cryptococcus neoformans - drug effects; Cryptococcus neoformans - isolation & purification; Drug Resistance, Fungal; Epidemiologic Methods; epidemiological cut-off value; Fluconazole - pharmacology; Flucytosine - pharmacology; HIV; HIV Infections - microbiology; Human immunodeficiency virus; Humans; Itraconazole - pharmacology; Meningitis, Cryptococcal - microbiology; Microbial Sensitivity Tests; Triazoles - pharmacology; Voriconazole - pharmacology
• ISSN: 0933-7407; 1439-0507
• DOI: 10.1111/myc.12479

Summary Epidemiological cut‐off values (ECVs) based on minimal inhibitory concentration (MIC) distribution have been recently proposed for some antifungal drug/Cryptococcus neoformans combinations. However, these ECVs vary according to the species studied, being serotypes and the geographical origin of strains, variables to be considered. The aims were to define the wild‐type (WT) population of the C. neoformans species complex (C. neoformans) isolated from patients living in Argentina, and to propose ECVs for six antifungal drugs. A total of 707 unique C. neoformans isolates obtained from HIV patients suffering cryptococcal meningitis were studied. The MIC of amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole was determined according to the EDef 7.2 (EUCAST) reference document. The MIC distribution, MIC50, MIC90 and ECV for each of these drugs were calculated. The highest ECV, which included ≥95% of the WT population modelled, was observed for flucytosine and fluconazole (32 μg ml−1 each). For amphotericin B, itraconazole, voriconazole and posaconazole, the ECVs were: 0.5, 0.5, 0.5 and 0.06 μg ml−1 respectively. The ECVs determined in this study may aid in identifying the C. neoformans strains circulating in Argentina with decreased susceptibility to the antifungal drugs tested.